Overview

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb